Suche
Mein Konto
Inventia Life Science is collaborating with Xylyx Bio to develop tissue-specific, digitally printed bioinks for drug discovery
September 1, 2021 – Inventia Life Science, a Sydney-based biotechnology company, and Xylyx Bio, a New York-based leader in advanced biomaterials, today announced their strategic partnership following promising results in developing more realistic, scalable and reproducible 3D cell cultures for drug discovery and biomedical Research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting offers promising tools to culture cells quickly and more precisely to develop more effective drugs. Inventia Life Science differentiates itself from other bioprinting solutions through its RASTRUM™ 3D cell culture platform, which provides biologists with easy access to large-scale, reproducible and customizable tissue models. Through …
Inventia Life Science is collaborating with Xylyx Bio to develop tissue-specific, digitally printed bioinks for drug discovery
September 1, 2021 – Inventia Life Science, a Sydney-based biotechnology company, and Xylyx Bio, a New York-based leader in advanced biomaterials, today announced their strategic partnership following promising results in developing more realistic, scalable and reproducible 3D cell cultures for drug discovery and biomedical Research.
As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting offers promising tools to culture cells quickly and more precisely to develop more effective drugs.
Inventia Life Science differentiates itself from other bioprinting solutions through its RASTRUM™ 3D cell culture platform, which provides biologists with easy access to large-scale, reproducible and customizable tissue models. By integrating liver-specific extracellular matrix (ECM) components developed by Xylyx Bio, the partners are developing robust bioprinted 3D liver tissue models. Inventia will complete product development and offer these solutions for research and drug discovery applications, with plans to expand to other tissue types.
Dr. John O’Neill, co-founder and chief scientific officer of
Dr. Julio Ribeiro, Founder and Chief Executive Officer of Inventia Life Science, is very excited about this partnership. He explained: "At Inventia Life Science, we strive to provide an automated 3D cell culture solution to accelerate drug discovery and biomedical research. This partnership with Xylyx is a significant step in the right direction to further expand our matrix portfolio to enable reproducible and tissue-specific generation of complex To enable tissue models.”
About Xylyx Bio
Xylyx Bio is a pioneer in advanced biomaterials, serving customers in research, clinical and commercial applications. The Company's products provide the full range of components from the natural cellular microenvironment essential for the most accurate and actionable results for scientists working in pharmaceutical development, cell biology research and regenerative medicine.
To find out more please contact:
Inventia Life Science
Dr. Duyen Nguyen
[email protected]
Xylyx Bio, Inc.
Tanya Yankelevich
[email protected]
.